

1 Strain-dependent induction of primary bile acid 7-dehydroxylation by cholic acid.

2 **Authors**

3 Eduard Vico-Oton¹, Colin Volet¹, Nicolas Jacquemin¹, Yuan Dong², Siegfried Hapfelmeier², Karin
4 Lederballe Meibom¹, Rizlan Bernier-Latmani^{1*}

5

6 ¹Environmental Microbiology Laboratory, School of Architecture, Civil and Environmental Engineering,
7 École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.

8 ²Institute for Infectious Diseases, University of Bern, Bern, Switzerland

9 *Corresponding author. E-mail address rizlan.bernier-latmani@epfl.ch. Postal address EPFL ENAC IIE
10 EML CH A1 375 (Bâtiment CH) Station 6 CH-1015 Lausanne Switzerland. Tel. +41 21 69 35001.

11 **Abstract (250 words)**

12 Bile acids (BAs) are steroid-derived molecules with important roles in digestion, the maintenance of
13 host metabolism and immunomodulation. Primary BAs are synthesised by the host, while secondary
14 BAs are produced by the gut microbiome through transformation of the former. Regulation of
15 microbial production of secondary BAs is not well understood, particularly the production of 7-
16 dehydroxylated BAs, which are the most potent agonists for host BA receptors. The 7-dehydroxylation
17 of cholic acid (CA) is well established and is linked to the expression of a bile acid-inducible (*bai*) operon
18 responsible for this process. However, little to no 7-dehydroxylation has been reported for other host-
19 derived BAs (e.g., chenodeoxycholic acid, CDCA or ursodeoxycholic acid, UDCA). Here, we
20 demonstrate that the 7-dehydroxylation of CDCA and UDCA by *Clostridium scindens* is induced by CA
21 suggesting that CA-dependent transcriptional regulation of 7-dehydroxylation is generalisable to
22 CDCA and UDCA. In contrast, the murine isolate *Extibacter muris* did not respond to CA exposure *in*
23 *vitro*, suggesting that *bai* genes are regulated differently in this strain. However, it could 7-
24 dehydroxylate *in vivo* and its *in vitro* activity was promoted by the addition of cecal content. The
25 accessory gene *baiJ* was only upregulated in the *Clostridium scindens* ATCC 35704 strain, implying
26 mechanistic differences amongst isolates. Interestingly, the human-derived *C. scindens* strains were
27 also capable of 7-dehydroxylating murine bile acids (muricholic acids) to a limited extent. This study
28 shows novel 7-dehydroxylation activity *in vitro* as a result of CA-driven induction and suggests distinct
29 *bai* gene induction mechanisms across bacterial species.

30 **Keywords**

31 7-dehydroxylation, *Clostridium scindens*, *Extibacter muris*, gut microbe, deoxycholic acid (DCA),
32 lithocholic acid (LCA), muricholic acid (MCA), ursodeoxycholic acid, CA co-induction, *bai* gene
33 expression, conjugated bile acids

34 **Introduction**

35 Primary bile acids (BAs) are metabolites synthesised from cholesterol by hepatocytes while secondary
36 BAs are produced by the gut microbiome through the transformation of primary BAs (Figure 1). In the
37 liver, the BA are conjugated to glycine or taurine. The three main microbial BA transformations are
38 deconjugation (loss of the amino acid group), oxidation (of one or several of the hydroxyl groups), and
39 7 α -dehydroxylation (7-DH-ion), the loss of a hydroxyl group at the C7 position¹. These microbial
40 transformations increase the diversity of the BA pool (Figure 1) and enhance BA affinity to host
41 receptors. In particular, 7-DH-ion turns primary BAs such as cholic acid (CA) and chenodeoxycholic acid

42 (CDCA) into the 7-dehydroxylated (7-DH-ed) BAs deoxycholic acid (DCA) and lithocholic acid (LCA),
43 respectively².

44 BAs act as detergents to solubilise dietary fats, but also have important metabolic and
45 immunomodulatory roles through activation of their target receptors³. The two best-studied BA
46 receptors are the Farnesoid X Receptor (FXR), a nuclear receptor, and the G Protein-Coupled Bile Acid
47 Receptor, GPBAR1, also known as Takeda G-Protein Receptor 5 (TGR5), which is a membrane receptor.
48 FXR is activated through the binding of BA agonists, particularly the 7-DH-ed LCA but also DCA⁴. FXR
49 activation results in the inhibition of primary BA synthesis through repression of the cholesterol 7 α -
50 hydroxylase CYP7A1. Regulation of BA production limits BA concentration and therefore, toxicity. On
51 the other hand, BA dysregulation can cause health issues such as cholestasis, irritable bowel
52 syndrome, gallstone disease, or even the induction of colorectal cancer⁵⁻⁷. Besides BA homeostasis,
53 FXR also has focal roles in glucose and lipid homeostasis⁸. Similarly, TGR5 is a multifunctional regulator
54 involved in glucose homeostasis, energy expenditure, and the modulation of the inflammatory
55 response^{9,10}. LCA, DCA and their tauro-conjugated forms TLCA and TDCA, are among the strongest
56 agonists of TGR5^{11,12}, highlighting the importance of microbial transformation, particularly 7-DH-ion,
57 in TGR5 activation. Moreover, DCA and LCA have protective properties against *Clostridium difficile*
58 infection^{13,14}.

59 The study of BAs has traditionally been based on mouse models¹⁵. Besides CA and CDCA, mice (and
60 other rodents) also generate muricholic acids (MCAs) such as α -MCA and β -MCA (Figure 1) and re-
61 hydroxylate DCA and LCA in the liver¹⁶. Additionally, the mouse liver is capable of producing primary
62 ursodeoxycholic acid (UDCA)¹⁶ although there is evidence that the gut microbiome is responsible for
63 a significant fraction of UDCA in the gut¹⁴. On the other hand, UDCA is exclusively a secondary BA in
64 humans⁷. Because 7-DH-ion plays a major role in host homeostasis, significant effort has been
65 expended to study 7-dehydroxylating (7-DH-ing) bacteria.

66 Nonetheless, experimental evidence of 7-DH-ion is limited to a few species of the *Clostridiales* order.
67 One of the best characterised is the human isolate *Clostridium scindens* ATCC 35704, the type strain
68 of *C. scindens*¹⁷. The *Extibacter muris* DSM 28560 (JM40) strain was recently isolated from mice and
69 identified as a 7-DH-ing organism^{18,19}. The ability of *C. scindens* ATCC 35704 to 7-dehydroxylate both
70 *in vivo* and *in vitro* is well established²⁰; *E. muris* has also been shown to 7-dehydroxylate *in vivo*,
71 transforming primary BAs CA, CDCA, α MCA, β MCA and UDCA into their respective secondary BAs DCA,
72 LCA and MDCA. Previous research had focused on *E. muris* strain DSM 28560²¹ and in this study, we
73 demonstrate that *E. muris* strain DSM 28561 (SJ24) also has the ability to 7-dehydroxylate (7-DH-ate)
74 *in vivo*.

75 The biochemical machinery for 7-DH-ion is encoded in the *bai* (bile acid inducible) eight-gene operon
76 (*baiBCDEA2FGHI*)²². In addition, the *C. scindens* ATCC 35704 strain harbours the accessory gene *baiJ*
77 (HDCHBGLK_03451)²³ whereas the *E. muris* DSM 28650 genome includes a *baiJKL* pseudogene
78 cluster²¹. Most of the published work on the 7-DH-ion pathway has been performed with another *C.*
79 *scindens* strain, VPI 12708^{24,25}. A recent publication by Funabashi *et al.* cloned the *bai* operon of *C.*
80 *scindens* VPI 12708 into *Clostridium sporogenes* which then showed *in vivo* 7-DH-ing activity²⁵.
81 Different strains exhibit varying efficiency in 7-DH-ing CA *in vitro*. The *C. scindens* ATCC 35704 and VPI
82 12708 strains show rapid transformation to DCA while *E. muris* DSM 28560 has more limited
83 activity^{19,20,26}. Other known 7-DH-ing strains such as *Clostridium hylemonae* and *Peptacetobacter*
84 *hiranonis* have been reported as harbouring weak and strong activity, respectively²⁷ and a new strain
85 of *P. hiranonis* recently isolated from dog faeces displayed *in vitro* 7-DH-ion at around 30% conversion

86 of CA to DCA²⁸. Notably, *in vitro* 7-DH-ion of other primary BAs has been reported to be minor (CDCA)
87 or non-existent (MCAs and UDCA)^{20,21,29}.

88 The limited *in vitro* 7-DH-ion of primary BAs other than CA (i.e., CDCA and MCAs) is striking considering
89 that secondary 7-DH-ed forms of these BAs are routinely detected at significant concentrations in the
90 host^{30,31}. Most studies tackling *in vitro* primary bile acid 7-DH-ion consider each BA in isolation. In
91 addition, significant overexpression of the *bai* operon in response to CA has been reported^{32,33} but
92 there is no information about the potential induction of this operon by other primary BAs (i.e., CDCA
93 and MCAs) and whether induction by CA also results in the transformation of the latter. We
94 hypothesise that CA-dependent induction of the *bai* operon promotes 7-DH-ing activity of other BAs
95 when they occur together with CA. Moreover, we posit that primary BAs other than CA cannot induce
96 their own transformation.

97 Here, the expression of *bai* genes was measured *in vitro* in the presence of CA, CDCA, α MCA, β MCA
98 and UDCA, with and without co-induction with CA to test whether the overexpression of *bai* genes
99 was exclusive to CA and whether CA-induced overexpression was sufficient to promote the 7-DH-ion
100 of other BAs. The experiments were performed with three strains, the human isolates *C. scindens* ATCC
101 35704 and VPI 12708 and the murine isolate *E. muris* DSM 28561 (SJ24). The results show that the
102 response to CA co-induction was strain-variable. It was highly effective for *C. scindens* strains and
103 sufficient to promote the transformation of other primary BAs. For *E. muris*, none of the BAs tested
104 promoted 7-DH-ion, nevertheless, a positive effect was observed when the bacterium was co-cultured
105 with a small amount of faecal content from germ-free mice, suggesting that signaling from the host
106 may be responsible for the induction of 7-DH-ion in *E. muris* SJ24.

107 This work highlights the importance of the presence CA for the 7-DH-ion of other BAs. Moreover,
108 results from *E. muris* SJ24 point at host-related differences whereby BAs may not be the key inducers
109 for BA 7-DH-ion in the murine gut.

110 **Results**

111 *In vitro* bile acid transformation and impact of ¹³C-CA co-induction

112 Two human isolates *C. scindens* ATCC 35704 and *C. scindens* VPI 12708 and one murine isolate *E. muris*
113 DSM 28561 (SJ24) were tested for their ability to 7-DH-ate human and mouse primary BAs *in vitro*. As
114 expected, all three strains 7-DH-ed CA but to varying extents (Figure 2). *C. scindens* ATCC 35704 and
115 *C. scindens* VPI 12708 showed strong 7-DH-ing activity with 97% and 80% CA conversion to 7-DH-ed
116 BAs after 48 hours, respectively. *E. muris* SJ24, on the other hand, only converted 9% of the CA
117 provided into 7-DH-ed forms (Figure 2). *C. scindens* ATCC 35704 produced up to 52.26 μ M DCA after
118 32 hours with some of the DCA subsequently oxidised to 12-oxolithocholic acid (12-oxoLCA) (Figure
119 2A). In contrast, *C. scindens* VPI 12708 produced the highest amount of DCA after 48 hours (71.42 μ M),
120 with little to no oxidised DCA forms (0.19 μ M of 3-oxoDCA at 48 hours) (Figure 2B). The lack of 12-oxo
121 forms from the *C. scindens* VPI 12708 strain was expected since the 12 α -hydroxysteroid
122 dehydrogenase (12 α -HSDH) required for this process was not detected by PCR in this strain (the full
123 genome is currently unavailable) (data not shown). Finally, *E. muris* SJ24 only produced 8.1 μ M of DCA
124 after 48 hours with very low amounts of oxidised forms of DCA (0.21 μ M of 12-oxoLCA) (Figure 2C). It
125 is important to highlight that *E. muris* does not possess a 3 α -HSDH encoded by *baiA2* which was
126 recently identified as an important component of the CA 7-DH-ion pathway²⁵. *BaiA1/3* has lower
127 affinity to CA than *BaiA2*³⁴ and is present outside the *bai* operon³⁵. Finally, all three strains also showed
128 a modicum of 7-oxidation activity (Figure 2), resulting in the formation of 7-oxoDCA, which cannot be
129 7-DH-ed. Moreover, parallel experiments were performed by amending the cultures with ¹³C-CA in

130 addition to other individual BAs in order to test whether the 7-DH-ion of CDCA, α MCA, β MCA and
131 UDCA could be induced by CA (Supplementary Table 1). Similar results to above were obtained for the
132 control (^{13}C -CA only) experiments (Supplementary Figure 1).

133 CDCA 7 α -dehydroxylation is very limited for all three strains. Indeed, *C. scindens* ATCC 35704 only
134 produced 1.59 μM LCA and *C. scindens* VPI 12708 only 1.55 μM LCA (Figure 3AB), whereas for *E. muris*,
135 no LCA was detected. The latter is in line with previous reports²¹. The amendment of ^{13}C -CA
136 significantly increased the transformation of CDCA for both *C. scindens* strains (p -value < 0.001 two-
137 way ANOVA) but had no impact on *E. muris* SJ24 (Figure 3C). Indeed, the LCA yield increased to 9.77
138 μM for strain ATCC 35704 and to 40.4 μM for strain VPI 12708 (Figure 3AB). No change was observed
139 for *E. muris* SJ24.

140 As for UDCA, 7 α -dehydroxylation to LCA was observed only upon amendment with ^{13}C -CA (Figure 4).
141 None of the strains exhibited any detectable level of activity from cultures that included only UDCA.
142 14.92 μM of LCA as well as extremely low amounts of 3-oxoLCA (with a maximum of 0.12 μM at 32
143 hours) were detected when *C. scindens* ATCC 35704 was co-induced. An unknown oxidised form
144 labelled X-oxoUDCA was detected with a maximum concentration of 2.41 μM after 32 hours (Figure
145 4A). It is likely that this BA corresponds to 3-oxoUDCA (3-oxo-7 β -hydroxy-5 β -cholan-24-oic acid) as we
146 can exclude 7-oxoLCA (the other product of oxidation of UDCA) (Figure 1). Another BA with the same
147 ionised mass as UDCA was detected at a maximum concentration of 4.24 μM after 24 hours. We
148 propose that this could be an isoform of UDCA with the hydroxyl group of the C3 carbon in the β
149 conformation (3 β ,7 β -dihydroxy-5 β -cholan-24-oic acid). However, the identity of these compounds
150 remains unconfirmed due to the lack of standards. Upon co-induction, the 7-DH-ing activity of *C.*
151 *scindens* VPI 12708 was comparable to that of the co-induced ATCC strain, with 13.61 μM of LCA and
152 0.68 μM of 3-oxoLCA after 48 hours (Figure 4B). X-oxoUDCA was also detected at very small
153 concentrations around 0.5 μM from 12 hours until the end of the experiment. The potential isoform
154 of UDCA was detected at up to 9.92 μM at the 24-hour time point. Following the same trend observed
155 with the other primary BAs, *E. muris* SJ24 did not show any detectable activity with UDCA even after
156 co-induction. The chromatograms for the unknown bile acids can be found in Supplementary Figure
157 2.

158 As expected, neither *C. scindens* strain nor *E. muris* were capable of α MCA 7 α -dehydroxylation in the
159 absence of ^{13}C -CA (Figure 5). *C. scindens* ATCC 35704 only produced minute amounts of an unknown
160 oxo form of α MCA (labelled Y-oxo α MCA) (0.85 μM at 32 hours). Once co-induced with ^{13}C -CA, 6-
161 oxoMDCA was detected at 2.7 μM after 48 hours in the *C. scindens* ATCC 35704 culture (Figure 5A).
162 This secondary bile acid has been 7 α -DH-ed but also the hydroxyl at C6 oxidised. Moreover, several
163 intermediates for which standards are unavailable were also detected after 48 hours. These were
164 unknown oxidised forms of α MCA (labelled X- and Y- oxo α MCA) at concentrations not exceeding 5 μM
165 each. A third unknown BA was detected (albeit at very low concentrations, 0.41 μM at 32 hours) with
166 the same mass as 6-oxoMDCA, suggesting that it is an MCA species with one oxidation and one
167 dehydroxylation. This would indicate the production of another 7 α -dehydroxylated form of α MCA *in*
168 *vitro* (Figure 1, Figure 5A). As for the ATCC 35704 strain, *C. scindens* VPI 12708 exhibited an increase
169 in the quantity of products from α MCA transformation in the presence of ^{13}C -CA relative to its absence
170 (Figure 5B). This includes the 7-DH-ed BA 6-oxoMDCA that reached a concentration of 8.18 μM after
171 48 hours and the X- and Y- α MCA forms that were detected at maximum concentrations of 4.22 μM
172 (4 hours) and 1.69 μM (32 hours), respectively. The aforementioned α MCA-derived bile acid with one
173 ketone group and one dehydroxylation was also detected at a maximum concentration of 3.49 μM
174 after 48 hours (Figure 5B). Surprisingly, *E. muris* SJ24 did not exhibit any observable 7-DH-ing activity
175 with or without ^{13}C -CA. Nevertheless, a small amount of X-oxo α MCA was detected at all time points,

176 with a stable concentration at around 2.4 μM without and 1.9 μM with ^{13}C -CA (Figure 5C). The results
177 for βMCA were very similar to those for αMCA and are discussed in further detail in the supplementary
178 information.

179 The concentration of ^{13}C -CA was also measured over time to ascertain that CA was being metabolised.
180 It was observed to decrease until it disappeared after 48 hours in the *C. scindens* strains except in the
181 presence of CDCA, for which the concentration decreased slowly over time. We attribute this
182 observation to the toxicity of CDCA at that concentration²⁰. On the other hand, the concentration of
183 ^{13}C -CA in *E. muris* remained stable over time and in all conditions (Supplementary Figure 3).

184

185 *Induction of bai gene expression in the presence of bile acids*

186 In order to assess whether the amendment of ^{13}C -CA to the culture induced the *bai* operon as
187 hypothesised, the relative expression of *baiCD* and of *baiE* were measured. In addition, the expression
188 of *baiI* (an accessory gene) was also monitored. Gene expression was normalised using at least three
189 reference genes and was calculated relative to the expression levels in a control group without BAs.
190 Both *E. muris* strains, that is JM40 (DSM 28560) and SJ24 (DSM 28561), have a truncated *baiI* gene²¹.
191 However, while the *baiI* pseudogene is interrupted by stop codons in strain JM40, it is not in strain
192 SJ24, making it worthwhile to investigate *baiI* in the latter strain (as was done in this study).
193 Additionally, *baiO* was also analysed for *E. muris* SJ24 as an alternative accessory *bai* gene³⁶.

194 Results show that the expression of *bai* operon genes in both *C. scindens* strains was highly
195 upregulated as a response to exposure to CA or to CDCA but not to the other BAs (Figure 6). CA and
196 CDCA are also the only two primary BAs for which *in vitro* 7-DH-ion data are already available²⁰.
197 Moreover, it is worth highlighting that CDCA was tested using a concentration of 200 μM vs. 100 μM
198 for CA.

199 For *C. scindens* ATCC 35704, the three genes tested were highly upregulated when ^{13}C -CA was present
200 along with another BA (UDCA, αMCA , or βMCA) (Figure 6A). In the CDCA dataset, statistically
201 significant differences relative to the uninduced conditions were observed and all genes were slightly
202 more upregulated in the presence of ^{13}C -CA (p -value < 0.001 linear model), but *baiCD* was more so
203 than the other genes (Figure 6A). Most interestingly, none of the other primary BAs activated the
204 expression of *bai* genes on their own, consistent with the lack of 7-DH-ing activity with these BA
205 substrates alone. However, the expression was brought up to levels higher than those observed for
206 CA once co-induced (Figure 6A).

207 A similar pattern was observed for *C. scindens* VPI 12708 but with the significant difference being that
208 *baiI* was not overexpressed under any conditions (Figure 6B) (p -value < 0.001 linear model). In the
209 CDCA dataset, the co-induction with ^{13}C -CA had an upregulatory effect if assessed with a paired
210 Wilcoxon test (Supplementary Figure 4) but this effect was not found to be significant when using the
211 linear statistical model displayed in Figure 6. It is worth noting that the expression data were obtained
212 from the mid- to late-log exponential phase (around 18 hours) when differences in activity between
213 uninduced and co-induced conditions are not very large (Figure 3B). Similarly to *C. scindens* ATCC
214 35704, co-induction had a dramatic effect on the expression levels of *baiCD* and *baiE* in the presence
215 of UDCA, αMCA , or βMCA , with upregulation reaching the expression levels observed with CA or CDCA
216 alone (Figure 6B).

217 *E. muris* SJ24 showed a slight upregulation of *baiCD* and *baiE* in the CA dataset but it was not significant
218 and did not translate to any of the other conditions (Figure 6C), consistent with its very poor 7-DH-ing

219 activity (Figure 2). As a matter of fact, the increased *baiCD* and *baiE* gene expression ratio observed in
220 the CA group was probably caused by one of the biological replicates which had a higher expression
221 level than the others.

222 Thus, CA had a large effect on *bai* expression which was strain specific. Genes of the *bai* operon in the
223 two *C. scindens* strains (ATCC 35704 and VPI 12708) exhibited a similar response to CA induction but
224 the accessory *baiI* differed in its response. It was upregulated in strain ATCC 35704 but not in strain
225 VPI 12708. In contrast, CA had no significant effect on the expression of all the *bai* genes considered
226 in *E. muris* SJ24.

227 The *rhaS_1* gene (HDCHBGLK_01429) is immediately upstream of the *bai* operon promoter on the
228 opposite strand and has also been proposed as bile acid regulatory A (*barA*) due to its potential
229 implication in *bai* regulation⁷. The expression of *rhaS1* and *rhaS2* (a copy of *rhaS1* elsewhere in the
230 genome) was shown to have background levels across BAs (Supplementary Figure 5). This was tested
231 in *C. scindens* ATCC 35704 without the amendment of ¹³C-CA. Results indicate that *rhaS* is not
232 upregulated by any of the BAs tested.

233 Thus, the question remains about the conditions propitious for *bai* gene expression and robust 7-DH-
234 ion in *E. muris* SJ24. We hypothesized that other mouse-specific BAs may be the key inducers

235 *bai* gene induction by other BAs in *E. muris* SJ24

236 Because the presence of ¹³C-CA did not induce *bai* genes in *E. muris* SJ24, we tested four BA cocktails
237 to probe whether other BAs commonly found in the BA pool could promote *bai* expression. The BA
238 pool was divided into four cocktails: tauro-conjugated BAs, oxidised BAs, sulfonated BAs and ωMCA.
239 The addition of these BAs did not yield the production of any detectable secondary BAs (Figure 7). A
240 small CA concentration (<2 μM) was detected in the tauro-BA cocktail (Figure 7A) but this was likely
241 the result of the presence of CA as an impurity in the TCA standard, as it was also detected at time 0.
242 In the oxidised BA cocktail, 12-oxoCDCA was almost fully reduced to CA after 16 hours (Figure 7B).
243 Small quantities of CDCA and βMCA were detected, while both are likely to be impurities from the
244 standards used (detected at time 0), it is worth highlighting that the concentration of CDCA increased
245 from an average of 2.74 μM (time 0) to 5.35 μM (time 24), meanwhile, the concentration of βMCA
246 remained stable around 2 μM. No reduction of 3-oxo forms was detected, likely due to the absence
247 of *baiA2*²⁵. Finally, neither sulfonated BAs nor ωMCA were transformed by *E. muris* SJ24 in any way
248 (Figure 7C-D). Therefore, we excluded the possibility that other BAs could induce *bai* expression and
249 7-DH-ing activity in *E. muris* SJ24.

250 The expression of *baiCD*, *baiE*, the pseudogene *baiI* and *baiO* was also measured in the BA cocktail
251 experiments and compared with a CA-only reference group. Given the lack of 7-DH-ion of the BAs
252 within the cocktails, it is not surprising that no significant upregulation was observed in any of the BA
253 cocktail groups when compared to the CA control. (Supplementary Figure 6A).

254 *Bile acid 7-DH-ion by E. muris* SJ24 in the presence of mouse cecal content

255 CA 7-DH-ion by *E. muris* SJ24 was investigated in the presence of cecal content from either germ-free
256 mice or a stable gnotobiotic murine model, Oligo-Mouse-Microbiota (Oligo-MM12)³⁷ in order to
257 further investigate potential non-BA triggers for 7-DH-ion. A significant fraction of CA was conjugated
258 with Co-enzyme A (CoA) and therefore could not be detected, as there are no standards for CoA-
259 forms. In the controls (no cecal content), the DCA concentration averaged 4.26 μM after 48 hours
260 which corresponded to the transformation of approximately 7% of the initial CA (Figure 8A). The
261 amendment of cecal content from germ-free mice increased the DCA produced to 7.6 μM which

262 corresponded to 12% of the initial CA (Figure 8B). Finally, the addition of cecal content from Oligo-
263 MM12 mice produced only 0.67 μ M of DCA but 18.6 μ M of 7-oxoDCA (Figure 8C). In all conditions,
264 DCA was detected after 12 hours of incubation and gradually increased. 12-oxoCDCA was detected in
265 all conditions, while 3-oxoCA was only found in the CA control and germ-free groups (Figure 8). The
266 control groups of cecal content without *E. muris* SJ24 showed no change in CA concentration other
267 than the potential conjugation with Co-A by the Oligo-MM12 mouse case (Supplementary Figure 7).

268 Despite the measurable impact on 7-DH-ion by the addition of germ-free mouse cecal content of CA
269 7-DH-ion, it was not sufficient to significantly upregulate *bai* expression when compared to the CA-
270 only reference group (Supplementary Figure 6B). In both assays, the gene expression ratio of *bai* genes
271 was never above 3.

272

273 *E. muris* SJ24 *In vivo* 7-DH-ion and *bai* gene expression

274 The ability of *E. muris* strain DSM 28560 (JM40) to 7-DH-ion *in vivo* has been previously documented²¹.
275 Here, colonisation of Oligo-MM12 mice was performed with the DSM 28561 strain (*E. muris* SJ24) to
276 confirm 7-DH-ion *in vivo* and quantify *bai* gene expression. The bile acid composition confirms active
277 7-DH-ion *in vivo* in Oligo-MM12 mice. Indeed, DCA, LCA and MDCA, were exclusively identified in the
278 sDMDMm2 + *E. muris* SJ24 group (Supplementary Figure 8).

279 As for the aforementioned expression assays, expression of *baiCD*, *baiE*, the pseudogene *baiI* and *baiO*
280 was quantified, normalised against at least three reference genes and calculated relative to the
281 background signal detected from non-specific amplification in the Oligo-MM12 mice (without *E. muris*
282 SJ24).

283 Results show the expression of *E. muris* SJ24 *bai* genes *in vivo* (Figure 9). Indeed, *baiE* was expressed
284 at significant levels above background (gene expression ratio of 35.9) while *baiCD* and the *baiI*
285 pseudogene had low gene expression ratios of 1.78 and 1.38, respectively. Finally, the expression ratio
286 of the auxiliary oxidoreductase *baiO* was situated at 4.04.

287

288 Discussion

289 Bile acid chemistry is a relevant field in human and veterinary medicine not only because of BA
290 detergent function during digestion but also for the wide range of roles related to host physiology and
291 homeostasis^{38,39}.

292 The *bai* operon was originally described in *C. scindens* VPI 12708 in 1990 and this strain has become
293 the reference for biochemical studies of the 7-DH-ion pathway^{22,35,40}. The operon (*baiBCDEFGHI*)
294 encodes one CoA ligase (*baiB*), two oxidoreductases (*baiCD* and *baiH*), a 7-dehydratase (*baiE*), a CoA
295 transferase (*baiF*), a transporter (*baiG*), and a putative ketosteroid isomerase (*baiI*), but not all genes
296 are required for 7-DH-ion²⁵. Expectedly from such a complex operon, comparative genomics have
297 highlighted significant differences in the *bai* operon amongst 7-DH-ing strains^{35,41}. Furthermore, a
298 novel genetic synteny has been recently described and proven to be capable of 7-DH-ion. This novel
299 synteny does not follow the traditional *bai* operon structure and instead breaks it down to smaller
300 operons that cluster together^{41,42}. Moreover, accessory *bai* genes have also been described across
301 multiple strains^{35,40}. These accessory genes often cluster in two operons *baiJKL* and *baiNO* which is not
302 always complete; *C. scindens* ATCC 35704 only has *baiI* (urocanate reductase)³² while the VPI 12708
303 strain has the full *baiJKL* set³⁵. From the genome analysis, *E. muris* SJ24 has fragments of *baiJKL* as

304 pseudogenes, while its sister strain JM40 has similar pseudogenes but interrupted by stop codons. The
305 exact role of these genes has yet to be defined.

306 Out of all primary BAs, only CA has been consistently reported to be 7-DH-ed *in vitro*. In contrast, CDCA
307 is poorly 7-DH-ed and other murine primary BAs (α MCA, β MCA or UDCA) are not at all^{20,21,43–46}. We
308 confirm that the two *C. scindens* human isolates upregulated the expression of *bai* operon genes in
309 response to CA (Figure 6), except for *baiI*. Indeed, we observed differences in the response of *baiI* to
310 CA in between the two strains. This accessory gene is annotated as an urocanate reductase and a
311 member of the oxidoreductase family. The current CA 7-DH-ion pathway would suggest that this gene
312 is not involved in that process in strain VPI 12708²⁵, which is consistent with the lack of expression
313 observed here (Figure 6B). Conversely, its high level of upregulation in the strain ATCC 35704 matches
314 previously published data³² and suggests that *baiI* may play a role in the 7-DH-ion of CA or other BAs
315 in that strain. Finally, *E. muris* SJ24, the murine isolate, barely registered any *bai* gene expression
316 response to CA or any other BA tested.

317 CDCA co-induction with ¹³C-CA was particularly effective in both *C. scindens* strains. The significant *bai*
318 upregulation (Figure 6) was reflected in an increase on the 7-DH-ed products from 1 to 5% in *C.*
319 *scindens* ATCC 35704 and a dramatic increase from 1 to 23% in *C. scindens* VPI 12708 (Figure 3). These
320 data suggest that the 7-DH-ion pathway of CDCA uses the same *bai* machinery as CA and its regulation
321 is dependent on the CA pathway. Furthermore, strain ATCC 35704 shows lower 7-DH-ion of CDCA
322 (Figure 3) and less effective 7-DH-ion of CA (Figure 2 and Supplementary Figure 1) as compared to
323 strain VPI 12708 despite a significant upregulation in *baiI* expression.

324 UDCA is the 7 β isomer of CDCA and is reported to have significant therapeutic properties^{2,7,47}. In
325 humans, UDCA is synthesised from CDCA by gut microbes containing 7 β -HSDHs^{7,26,48,49} and is thus, a
326 secondary BA; in mice, it is produced by the liver, thus, it is a primary BA, and is used as a precursor
327 for β MCA^{15,16}. Nevertheless, colonisation of mice lacking 7-dehydroxylating bacteria with 7-DH-ing
328 bacteria increases UDCA levels, implying that the gut microbiome also plays a significant role in UDCA
329 production by mice¹⁴. Despite the importance of this BA for medical applications, little is known about
330 the capacity of bacteria to 7 β -dehydroxylate UDCA *in vitro*. Previous work has reported no
331 transformation by *C. scindens* strain ATCC 35704²⁰. In accordance with our hypothesis, co-induction
332 with ¹³C-CA not only greatly upregulated *bai* gene expression (Figure 6B) but also provided evidence
333 of UDCA 7 β -dehydroxylation as LCA was detected in the culture (Figure 4). Indeed, the amount of 7-
334 DH-ed products upon co-induction increased from 0 to 15 and 16% in *C. scindens* strains ATCC 35704
335 and VPI 12708, respectively. The absence of CDCA in the culture suggests that UDCA was not
336 epimerised to CDCA and subsequently 7 α -dehydroxylated. Moreover, two unidentified compounds
337 consistent with 7 β -dehydroxylation were detected, providing further evidence of the 7 β -
338 dehydroxylation of UDCA and its associated unique set of intermediates. The oxidised intermediate is
339 very likely to be 3-oxoUDCA (3-oxo-7 β -hydroxy-5 β -cholan-24-oic acid), as based on the mass, the only
340 alternative would have been 7-oxoLCA, which can be excluded as it is one the standards within our
341 collection (Figure 4). The other unknown compound had the same mass as UDCA albeit a different
342 retention time, suggesting this could be an iso- form of UDCA. It follows that this would be 3 β -UDCA,
343 tentatively named isoUDCA (3 β ,7 β -dihydroxy-5 β -cholan-24-oic acid). Isoforms are well known in the
344 BA pool and particularly in CDCA-related intermediates^{20,25,33,50} so it is likely that UDCA follows a similar
345 pattern. Despite the production of unknown intermediates, the activity response to co-induction
346 suggests that UDCA 7 β -dehydroxylation uses the same *Bai* machinery as CDCA 7-DH-ion.

347 7-DH-ion activity was uncovered for α MCA and β MCA, for the first time and it yielded several
348 intermediate BAs that we were not able to fully characterise due to the lack of appropriate standards.

349 All human and mouse BAs share a backbone of four rings (Figure 1), this makes mass fractionation in
350 the mass spectrometer unsuitable for identification. Therefore, we currently rely on comparison of
351 ionised mass and retention time to standards. However, several assumptions can be made to
352 speculate what these compounds could be. MCAs could be oxidised at the C-3, C-6 or C-7 position
353 (Figure 1). A C-7 oxidation would yield 7-oxoMDCA regardless of the primary MCA. Meanwhile, other
354 oxidations could be differentiated by the α or β conformation of the C-7 hydroxyl. It is possible that
355 one of the intermediates that we detected was 7-oxoMDCA but none shared retention times across
356 MCAs, meaning that different intermediates were produced for each of the two MCA substrates
357 (Supplementary Figure 2). Considering that distinct oxidised intermediates were detected for the two
358 MCAs, we hypothesise that those are the 3-oxo and 6-oxo forms of α MCA and β MCA (3-oxo α MCA: 3-
359 oxo-6 β ,7 α -dihydroxy-5 β -cholan-24-oic acid; 6-oxo α MCA: 6-oxo-3 α ,7 α -dihydroxy-5 β -cholan-24-oic
360 acid; 3-oxo β MCA: 3-oxo-6 β ,7 β -dihydroxy-5 β -cholan-24-oic acid; and 6-oxo β MCA: 6-oxo-3 α ,7 β -
361 dihydroxy-5 β -cholan-24-oic acid). A third intermediate was also detected from both MCAs, with the
362 ionised mass corresponding to secondary BAs with one dehydroxylation and a ketone group (e.g., 7-
363 oxoLCA) (Figure 5 & Supplementary Figure 9). Three options are plausible: 1) A dehydroxylation at the
364 C-3 position. This would yield a novel family of BAs with a 6 β - and 7 α/β - hydroxyls which is highly
365 unlikely as it would have been identified previously by the multiple studies investigating the murine
366 BA pool^{15,16,51-54}. 2) An oxidation paired with a 6-dehydroxylation would yield 3-oxoCDCA, 7-oxoLCA,
367 or 3-oxoUDCA. 3-oxoCDCA and 7-oxoLCA were included as standards in our analysis (Supplementary
368 Table 3) and would have been detected if present. Meanwhile, the retention time of this compound
369 is distinct from that of the compound proposed to be 3-oxoUDCA from the transformation of UDCA
370 (see above and Supplementary Figure 2). Thus, this is not likely to be 3-oxoUDCA. 3) A 7-
371 dehydroxylation could allow for ketone groups at the C-3 and C-6 positions. 6-oxoMDCA was available
372 as a standard but, the second option, 3-oxoMDCA (3-oxo-6 β -hydroxy-5 β -cholan-24-oic acid), was not.
373 It is therefore possible that this compound corresponds to 3-oxoMDCA, but this remains to be
374 confirmed.

375 The mouse BA pool is significantly more diverse than that of humans due to the primary production
376 of muricholic acids (with a hydroxyl group at the C-6 position) and of UDCA. The murine secondary BA
377 pool includes DCA and LCA but also MDCA and its 6 α counterpart, hyodeoxycholic acid (HDCA).
378 Furthermore, mice can rehydroxylate TDCA back into TCA in the liver¹⁵ which magnifies the differences
379 between mouse and human BA pools. In general, the secondary BAs derived from muricholic acids
380 seem to be in low abundance in the gut, hinting at the difficulty in 7-DH-ing these BAs. This is perhaps
381 the reason why primary BAs such as β MCA are highly abundant in the mouse BA pool⁵⁵. While we
382 initially hypothesised that the lack of 7-DH-ion activity for α MCA and β MCA was due to the lack of *bai*
383 gene expression, our co-induced data show that even *bai* gene expression in the *C. scindens* strains is
384 insufficient for the production of MDCA²¹, and results in the detection of potential oxidized versions
385 of that BA (Figure 5 and Supplementary Figure 9).

386 As reported above, the murine strain SJ24 has shown no significant *bai* upregulation nor 7-DH-ion *in*
387 *vitro* either in the presence or absence of ¹³C-CA. To investigate the underlying reasons for this lack of
388 activity, we considered three additional conditions: (a) various BA mixtures, to determine whether *bai*
389 gene expression was controlled by another (or several other) murine BAs; (b) *in vitro* in the presence
390 of Germ-free or Oligo-MM12 cecal content to ascertain whether the presence of other gut bacteria or
391 signalling molecules from the host itself induced 7-DH-ion; or (c) in the Oligo-MM12 environment, to
392 confirm the activity of strain SJ24 *in vivo*.

393 First, the *in vivo* condition exhibited high upregulation of *baiE* relative to the background, non-
394 colonised control (Figure 9) and 7-DH-ed BAs were detected in the BA pool from the same samples

395 (Supplementary Figure 8). On the other hand, *baiCD* did not show evidence of upregulation. It is
396 possible that the expression of *baiCD* by *E. muris* is constitutive while *baiE*, a 7 α -dehydratase⁵⁶,
397 presents a higher expression ratio, perhaps due to the smaller size of the protein (169 aa in *E. muris*
398 SJ24), intra-operon regulatory elements, or differential mRNA half-life⁵⁷. The expression of *baiO*, a
399 different oxidoreductase, was slightly above that of *baiCD*. Whilst the gene expression ratios remained
400 low in both instances, a role in 7-DH-ion by this protein cannot be ruled out. Thus, *E. muris* SJ24 is
401 capable of *in vivo* 7-DH-ion, although its *bai* machinery may require additional genes that have not
402 been identified in this study. However, the exact trigger for *in vivo* levels of 7-DH-ion from *E. muris*
403 still remained elusive at this point.

404 To elucidate that question, we tested all the BAs detected in the Oligo-MM12 environment, and found
405 no evidence of 7-DH-ing activity (Figure 7), excluding the possibility that non-CA BA triggered *bai* gene
406 expression in *E. muris*.

407 However, when SJ24 was grown in the presence of cecal content from germ-free mice, its 7-DH-ing
408 activity increased (Figure 8) despite *bai* gene expression not increasing significantly (Supplementary
409 Figure 6B). Indeed, the amendment of cecal content from germ-free mice (Figure 8B) resulted in a
410 significant increase from 7 to 13% of 7-DH-ed products, coupled with a decrease of the abundance of
411 the 12-oxoCDCA (3 α ,7 α -dihydroxy-12-oxo-5 β -cholanic acid) intermediate. Interestingly, the co-
412 cultivation of *E. muris* with the non-sterile cecal-content from Oligo-MM12 mice produced high
413 amounts of 7-oxoDCA (Figure 8C) while CA was not transformed by the same cecal content in the
414 absence of strain SJ24 (Supplementary Figure 7). This could suggest an interaction between *E. muris*
415 and the gnotobiotic community in which the former would promote the 7-oxidation of CA by the
416 latter, known to harbor 7-HSDHs⁵⁸. This interaction appears to be exclusive to the *in vitro* environment
417 since the *in vivo* BA data show lower concentrations of 7-oxoDCA than DCA (Supplementary Figure 8).

418 The evidence presented in this study shows that the role of the host, presumably through signalling,
419 is a critical element for effective 7-DH-ion by *E. muris* and the regulatory mechanisms of this secondary
420 BA transformation is dramatically different amongst bacterial species. The results also highlight the
421 significant differences in 7-DH-ion between human and mouse isolates but also between the *in vitro*
422 and *in vivo* environments.

423 To further highlight the differences, the human isolates showed marginal activity for α MCA and β MCA
424 upon co-induction. 7-DH-ed forms such as 6-oxoMDCA were detected (Figure 5 & Supplementary
425 Figure 9) but the full 7-dehydroxylation to MDCA was not observed. These data add further evidence
426 that other elements besides the *bai* operon (and *baiJ*) might be needed to completely 7-dehydroxylate
427 MCAs. Perhaps, a missing 6 β -HSDH gene would be required for complete 7-DH-ion. The apparent
428 simplicity of 7-DH-ion regulation from human isolates compared to that of *E. muris* could be due to
429 the more diverse diet of humans than mice. It has been observed that a less diverse diet can
430 overstimulate the BA pool in humans and increase the incidence of colorectal cancer⁵⁹. The natural
431 mouse diet is less diverse than that of humans and their initial lactation period (a monotrophic diet)
432 plays a much stronger role in the mouse lifespan⁶⁰. In these circumstances, a strong regulation of 7-
433 DH-ion might be an important mechanism to prevent BA pool unbalances. Nevertheless, much more
434 data on the 7-DH-ion mechanisms of various strains with particular focus on isolates from the mouse
435 and other animal models is required to investigate the potential differences in 7-DH-ion regulation.

436

437 **Conclusion**

438 The findings presented here are fourfold. First, we demonstrated that the previously reported^{32,33}
439 strong upregulation of *bai* genes by CA increases the extent of 7-DH-ion of other primary BAs. This
440 was particularly true for UDCA which has been reported to be converted to LCA *in vitro* for the first
441 time, with important differences in the 7-DH-ing capabilities amongst strains.

442 Secondly, the upregulation of *bai* genes exhibited strain-specific differences. *C. scindens* ATCC 35704
443 upregulated the *bai* operon genes *baiCD* and *baiE* as well as the *bai* accessory gene *baiJ*. While for *C.*
444 *scindens* VPI 12708, it upregulated the *bai* operon genes, but *baiJ* expression was found to be at a
445 background level. This is consistent with the lack of involvement of *baiJ* in 7-DH-ion in strain VPI
446 12708²⁵. *E. muris* SJ24 was the third bacterium tested, a murine isolate with *in vivo* 7-DH-ing
447 capabilities (Supplementary Figure 8). Strain SJ24 showed weak *in vitro* 7-DH-ion of CA and no
448 upregulation of any of the *bai* genes tested. The activity of this strain was promoted by the addition
449 of germ-free cecal content but not cecal content from Oligo-MM12 colonized mice. This result
450 suggests that host signalling is required for efficient 7-DH-ing activity by strain SJ24 but that the
451 presence of a minimum microbiome (12 strains) inhibits this activity potentially due to the promotion
452 of 7-HSDH activity from the microbiome *in vitro*. Unravelling the controls on BA 7-DH-ion by *E. muris*
453 requires further investigation.

454 Thirdly, *C. scindens* human isolates can partially 7-dehydroxylate MCAs, leading to the formation of
455 oxidized MDCA at the C-6 position. Therefore, an enzyme capable of reducing this compound, e.g., a
456 6 β -HSDH, is required to achieve the end point of 7-DH-ion that is observed *in vivo*, namely MDCA. To
457 date, such protein has not been identified in any microorganism.

458 Finally, the mechanism of 7-DH-ion regulation differs significantly between murine- and human-
459 derived strains, which could be due to the nature of the host. Human isolates showcase a system
460 governed by CA, while murine isolates appear to utilise a BA-independent signal present in the lumen.

461 In conclusion, these data provide novel insights into the intricacies of 7-DH-ion and the significant
462 differences amongst 7-DH-ing bacteria. The CA-dependent co-induction can be attributed to the
463 abundance of this compound in the BA pool of humans. However, the inducing factor for *E. muris*
464 activity remains elusive despite evidence suggesting that it is host-derived. Moreover, multiple novel
465 BAs were observed and their identity surmised. Further work with these and other strains is required
466 to investigate the 7-DH-ion pathway of CDCA, α MCA, β MCA and UDCA as well as to explore the strain-
467 specific differences regarding the 7-DH-ion pathway of CA.

468 **Materials and Methods**

469 Bacterial strains and growth conditions

470 The strains used were *Clostridium scindens* ATCC 35704, *Clostridium scindens* VPI 12708 and *Extibacter*
471 *muris* DSM 28561 (SJ24), this strain was chosen instead of *E. muris* DSM 28560 (JM40) due to its ability
472 to grow faster *in vitro* (24h vs 48h, data not shown). Bacteria were grown in Brain Heart Infusion
473 Supplement – Salts (BHI-S) medium, consisting of 37g BHI, 1g L-cysteine, 5g yeast extract, 2.5g
474 fructose, 50mL salts solution (0.2g CaCl₂, 0.2 MgSO₄, 1g K₂HPO₄, 1g KH₂PO₄, 10g NAHCO₃ and 2g NaCl
475 per L of ddH₂O) per L ddH₂O. The salts solution and media were sterilised by autoclaving. Static growth
476 was carried out at 37°C in an anoxic chamber (Coy Laboratory Products, 95% N₂, 5% H₂). A pre-
477 inoculum was prepared from glycerol stocks (using BHIS-S) before inoculating 25 mL of BHIS-S in
478 Falcon tubes at a starting OD₆₀₀ of 0.05. Results of the growth curves for the experiments can be found
479 in the Supplementary Information (Supplementary Figure 10).

480 *In vitro* 7-dehydroxylation assays

481 Bacteria were grown in presence of BAs: CA (100 μ M), CDCA (200 μ M), α MCA (100 μ M), β MCA (100
482 μ M) and UDCA (100 μ M) or the same volume of ethanol (solvent control). A sterile control (media
483 with ethanol solvent) was also included. Co-induction was performed by adding an additional 100 μ M
484 of 13 C-CA to CDCA, UDCA, α MCA, or β MCA). 13 C-CA was chosen so its transformation products could
485 be separated from those of the other primary BAs during the quantification process. All uninduced
486 experiments were conducted at the same time while all the co-induced ones were run simultaneously
487 at a different time. Both experiments included a condition consisting of the amendment of only 100
488 μ M CA, which allows for comparison of the results from co-induced and uninduced experiments.
489 Growth was monitored by periodically measuring the OD₆₀₀. During the main time points (0, 4, 8, 12,
490 24, 32 and 48 hours), 1mL samples were collected for BA extraction in a 2 mL bead-beating resistant
491 tube. All conditions were performed in triplicates.

492 Four BA cocktails were prepared for the assays with *E. muris* SJ24 based on the BAs often present in a
493 meaningful amount within the BA pool of mice. All BAs within the cocktails were at 50 μ M. The Tauro-
494 conjugated cocktail included TCA, TCDCA, T α MCA, T β MCA, TUDCA and THCA. The Oxo- cocktail
495 included 3-oxoCA, 3-oxoCDCA, 7-oxoDCA and 12-oxoCDCA. The Sulfo- cocktail included CA7S and
496 CDCA3S. Finally, the last group was only comprised of 50 μ M of ω MCA. All BAs were diluted in ethanol
497 or methanol depending on their solubility. Three time points were collected (0, 16 and 24 hours).

498 Furthermore, *E. muris* SJ24 was also amended with cecal content to test its implications over 7-DH-
499 ion *in vitro*. For this assay, 25 mg of freeze-dried cecal content from germ-free mice or 25 mg of frozen
500 content with 5% glycerol (v/v) from sDMDMm2 mice were added to 25 mL of BHIS-S with 100 μ M CA.
501 The control conditions for this experiment were a group with 100 μ M CA but no additional cecal
502 content and two more groups with each respective type of cecal content but no *E. muris* SJ24. Seven
503 time points were taken (0, 4, 8, 12, 24, 32 and 48). RNA sample collection was particularly early for
504 this experiment (4-hour time point) due to a faster-than-usual growth (Supplementary Figure 10).

505 *Bile acid extraction*

506 Samples were vacuum dried overnight (ON). Approximately 450 mg of 0.5 mm zirconium beads were
507 added to the dried samples as well as 500 μ L ice-cold alkaline acetonitrile (acetonitrile – 25% ammonia
508 4:1 v/v) and 100 μ L of ISTD solution (CA-d₄, CDCA-d₄, TCA-d₄, TUDCA-d₄, DCA-d₄ and LCA-d₄, each at
509 100 μ M in methanol). Samples were homogenised in a Precellys 24 Tissue Homogenizer (Bertin
510 Instruments, Montigny-le Bretonneux, France) at 6500 rpm 3x 30" beat 30" rest. Samples were
511 vortexed for 1 hour and centrifugated for 15 minutes at 16000 rcf at room temperature.
512 Approximately 500 μ L of suspension was carefully collected over the beads level and transferred into
513 a new 1.5 mL epi tube which was then vacuum dried overnight. Finally, the samples were reconstituted
514 in 1 mL of ammonium acetate [5mM] – methanol (50:50 v/v) and a 1:20 dilution with the same solvent
515 was prepared in LC-MS glass vials, ready for injection.

516 *RNA extraction and reverse transcription*

517 1 mL of sample was collected in a 15 mL falcon tube during the mid-log to late-log phase for the RNA
518 extraction. The sample was stored with RNa protect following the manufacturer protocol (Protocol 5
519 from RNa protect Bacteria Reagent Handbook 01/2020, Qiagen) at -80°C until processed. All conditions
520 were performed in triplicates. Lysis and RNA purifications were done using the RNeasy Mini Kit
521 (Qiagen, Hilden, Germany). Bacterial lysis was performed following Protocol 5: Enzymatic Lysis,
522 Proteinase K Digestion and Mechanical Disruption of Bacteria (RNa protect Bacteria Reagent
523 Handbook 01/2020, Qiagen), with 20 μ L of proteinase K for each sample and the required volumes for
524 a number of bacteria <7.5 x 10⁸. The cell lysis was performed using a Precellys 24 Tissue Homogenizer

525 (Bertin Instruments, Montigny-le-Bretonneux, France) at 6500 rpm 3x 10 seconds beat 10 seconds
526 rest. RNA purification was performed following Protocol 7: Purification of Total RNA from Bacterial
527 Lysate using the RNeasy Mini Kit. Centrifugations were carried out at 15000 rcf except for the 2 min
528 centrifugation which was done at 18000 rcf.

529 Purified RNA was further subject to a DNase treatment using the RQ DNase I (Promega, Madison, WI,
530 USA) following the manufacturer protocol with small modifications: The final volume was adjusted to
531 a 100 μ L and incubation was extended to 1 hour at 37°C. The treated RNA was cleaned-up using the
532 RNeasy Mini Kit (Qiagen, Hilden, Germany) following the RNA Clean-up protocol from the
533 manufacturer (RNeasy Mini Handbook 10/2019) with the 2 min centrifugation done at 18000 rcf.
534 Concentration and purity of RNA was measured with a NanoDrop One (Thermo Fisher Scientific,
535 Waltham, MA, USA).

536 100 ng of RNA was reverse transcribed into cDNA using the GoScript™ Reverse Transcription Mix,
537 Random Primers (Promega, Madison, WI, USA) following the manufacturer protocol. The process was
538 done in duplicates with one group using water instead of the reaction buffer as a non-reverse
539 transcription control (NRT).

540 *Reverse transcription quantitative PCR (RT-qPCR)*

541 RT-qPCRs were prepared using the Myra liquid handling system (Bio Molecular Systems, software
542 version 1.6.26) and performed using the Magnetic induction cyler (Mic) platform (Bio Molecular
543 Systems, Upper Coomera, QLD, Australia) with the micPCR software (v2.10.5).

544 The list of primers used can be found in Supplementary table 2. Samples were prepared with the
545 SensiFAST SYBR No-ROX Kit (Meridian Bioscience, Cincinnati, OH, USA) at a final volume of 10 μ L. All
546 runs were performed with the following program, with small modifications: Initial hold at 95°C for 5
547 minutes with a cycle of 95°C for 5 seconds, 54.5°C for 20 seconds (54.1°C for *E. muris* SJ24) and 72°C
548 for 9 seconds. 40 cycles were done for *C. scindens* ATCC 35704 and 50 for *C. scindens* VPI 12708 and
549 *E. muris* SJ24. The melting curve, temperature control and acquisition settings were left as default.
550 The quantification was done using three or more reference genes (Supplementary Table 2) based on
551 their expression stability across conditions. NRTs as well as no template controls (NTCs) were included
552 to check for residual DNA or contaminations. Four technical replicates were done for each biological
553 replicate. Note that expression data presented in Figure 6 for the CA-only condition (labelled CA)
554 correspond to the pooled expression results (for the condition in which only 100 μ M Ca was added)
555 from the two sets of experiments presented above (referred to as the co-induced and the uninduced
556 experiments, respectively). The *in vivo* expression data presented in Figure 9 was normalised against
557 the background signal detected from an uncolonised Oligo-MM12 control group.

558 *Liquid chromatography – mass spectrometry (LC-MS)*

559 The quantitative method was performed on an Agilent ultrahigh-performance liquid chromatography
560 1290 series coupled in tandem to an Agilent 6530 Accurate-Mass Q-TOF mass spectrometer. The
561 separation was done on a Zorbax Eclipse Plus C18 column (2.1 x 100mm, 1.8 μ m) and a guard column
562 Zorbax Eclipse Plus C18 (2.1 x 5mm, 1.8 μ m) both provided by Agilent technologies (Santa Clara, CA,
563 USA). The column compartment was kept heated at 50°C. Two different solutions were used as
564 eluents: ammonium acetate [5mM] in water as mobile phase A and pure acetonitrile as mobile phase
565 B. A constant flow of 0.4 mL/min was maintained over 26 minutes of run time with the following
566 gradient (expressed in eluent B percentage): 0-5.5 min, constant 21.5% B; 5.5-6 min, 21.5-24.5% B; 6-
567 10 min, 24.5-25% B; 10-10.5 min, 25-29% B; 10.5-14.5 min, isocratic 29% B; 14.5-15 min, 29-40% B;
568 15-18 min, 40-45% B; 18-20.5 min, 45-95% B; 20.5-23 min, constant 95% B; 23-23.1 min, 95-21.5% B;

569 23.10-26 min, isocratic 21.50% B. The system equilibration was implemented at the end of the
570 gradient for 3 minutes in initial conditions. The autosampler temperature was maintained at 10°C and
571 the injection volume was 5µL. The ionisation mode was operated in negative mode for the detection
572 using the Dual AJS Jet stream ESI Assembly. The QTOF acquisition settings were configured in 4GHz
573 high-resolution mode (resolution 17000 FWHM at m/z 1000), data storage in profile mode and the
574 high-resolution full MS chromatograms were acquired over the range of m/z 100-1700 at a rate of 3
575 spectra/s. The mass spectrometer was calibrated in negative mode using ESI-L solution from Agilent
576 technologies every 6 hours to maintain the best possible mass accuracy. Source parameters were
577 setup as follows: drying gas flow, 8 L/min; gas temperature, 300°C; nebulizer pressure, 35psi; capillary
578 voltage, 3500V; nozzle voltage, 1000V. Data were processed afterwards using the MassHunter
579 Quantitative software and MassHunter Qualitative software to control the mass accuracy for each
580 run. In the quantitative method, 42 bile acids were quantified by calibration curves (Supplementary
581 Table 3). The quantification was corrected by addition of internal standards in all samples and
582 calibration levels. Extracted ion chromatograms were generated using a retention time window of ±
583 1.5 min and a mass extraction window of ± 30ppm around the theoretical mass of the targeted bile
584 acid. Unknown BAs were identified when found within the retention time window of a standard with
585 the same ionised mass. Approximate quantification of these unknown BAs was done by using the
586 nearest standard (by retention time) with the same ionised mass.

587 Animals and Ethics Statement

588 sDMDMm2⁶¹ mice were housed in the Clean Mouse Facility (CMF, Department of Clinical Research) of
589 the University of Bern. Animal experiments were performed in accordance with the Swiss Federal and
590 the Bernese Cantonal regulations and were approved by the Bernese Cantonal ethical committee for
591 animal experiments under the license number BE82/13.

592 *In vivo* colonisation with *E. muris* SJ24

593 A cohort of nine sDMDMm2⁶¹ mice were used. Four mice were dedicated to an uncolonized control
594 group and the remaining five were colonised with *E. muris* DSM 28561 (SJ24). sDMDMm2 animals to
595 be colonised were imported from breeding isolators into small experimental isolators and
596 administrated orally with approximately 10⁹ CFUs (in 200 µL). Control animals remained in the
597 breeding isolator during this period. After 11 days, all animals were exported into a laminar flow hood
598 and sacrificed. Cecal content was collected for bile acid measurement and RNA extractions. RNA was
599 extracted from 75-100 mg of cecal content obtained at the end of the experiment (11 days from the
600 initiation of the colonisation experiment). 20 to 50 mg (dry weight) of cecal content were used for BA
601 extraction. BA quantification and RT-qPCR assays were performed as described above.

602 *Statistical analysis and data visualisation*

603 Graphpad Prism 9.2.0 (GraphPad) was used to generate the figures shown in this paper and perform
604 pairwise comparisons, the gene expression data was analysed with a linear model (LM) in R language
605 v4.1.2⁶² using RStudio⁶³ a 2-way ANOVA or a Welch's t-test. The statistical significance boundary was
606 established at a *p*-value < 0.05. **Conflicts of interest**

607 The authors declare no conflicts of interest.

608 **Data Availability Statement**

609 The data used for this manuscript are publicly available in the following link:

610 <https://doi.org/10.5281/zenodo.6034320>

611 **Funding**

612 The research hereby shown was funded by the Swiss National Science Foundation (Sinergia
613 CRSII5_180317)

614

615 **References**

- 616 1. Monte MJ, Marin JJG, Antelo A, Vazquez-Tato J. Bile acids: Chemistry, physiology, and
617 pathophysiology. *World J Gastroenterol* 2009; 15:804–16. doi: 10.3748/wjg.15.804
- 618 2. Hanafi NI, Mohamed AS, Kadir SHSA, Othman MHD. Overview of bile acids signaling and
619 perspective on the signal of ursodeoxycholic acid, the most hydrophilic bile acid, in the heart.
620 *Biomolecules* 2018; 8. doi: 10.3390/biom8040159
- 621 3. Kuipers F, Bloks VW, Groen AK. Beyond intestinal soap - Bile acids in metabolic control. *Nat Rev*
622 *Endocrinol* 2014; 10:488–98. doi: 10.1038/nrendo.2014.60
- 623 4. Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the
624 nuclear receptor FXR/BAR. *Mol Cell* 1999; 3:543–53. doi: 10.1016/S1097-2765(00)80348-2
- 625 5. Bernstein H, Bernstein C, Payne CM, Dvorakova K, Garewal H. Bile acids as carcinogens in
626 human gastrointestinal cancers. *Mutat Res - Rev Mutat Res* 2005; 589:47–65. doi:
627 10.1016/j.mrrev.2004.08.001
- 628 6. Joyce SA, Gahan CGM. Bile Acid Modifications at the Microbe-Host Interface: Potential for
629 Nutraceutical and Pharmaceutical Interventions in Host Health. *Annu Rev Food Sci Technol*
630 2016; 7:313–33. doi: 10.1146/annurev-food-041715-033159
- 631 7. Ridlon JM, Kang D-JJ, Hylemon PB, Ridlon JM, Kang D-JJ, Hylemon PB. Bile salt
632 biotransformations by human intestinal bacteria. *J Lipid Res* 2006; 47:241–59. doi:
633 10.1194/jlr.R500013-JLR200
- 634 8. Claudel T, Staels B, Kuipers F. The Farnesoid X receptor: A molecular link between bile acid and
635 lipid and glucose metabolism. *Arterioscler. Thromb. Vasc. Biol.* 2005; 25:2020–31. doi:
636 10.1161/01.ATV.0000178994.21828.a7
- 637 9. Guo C, Chen WD, Wang YD. TGR5, not only a metabolic regulator. *Front. Physiol.* 2016; 7. doi:
638 10.3389/fphys.2016.00646
- 639 10. van Nierop FS, Scheltema MJ, Eggink HM, Pols TW, Sonne DP, Knop FK, Soeters MR. Clinical
640 relevance of the bile acid receptor TGR5 in metabolism. *Lancet Diabetes Endocrinol* 2016;
641 5:224–33. doi: 10.1016/S2213-8587(16)30155-3
- 642 11. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, Fukusumi S, Habata Y, Itoh T,
643 Shintani Y, et al. A G protein-coupled receptor responsive to bile acids. *J Biol Chem* 2003;
644 278:9435–40. doi: 10.1074/jbc.M209706200
- 645 12. Brighton CA, Rievaj J, Kuhre RE, Glass LL, Schoonjans K, Holst JJ, Gribble FM, Reimann F. Bile
646 acids trigger GLP-1 release predominantly by accessing basolaterally located G protein-coupled
647 bile acid receptors. *Endocrinology* 2015; 156:3961–70. doi: 10.1210/en.2015-1321
- 648 13. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale
649 A, et al. Precision microbiome reconstitution restores bile acid mediated resistance to
650 *Clostridium difficile*. *Nature* 2015; 517:205–8. doi: 10.1038/nature13828
- 651 14. Studer N, Desharnais L, Beutler M, Brugiroux S, Terrazos MA, Menin L, Schürch CM, McCoy KD,

- 652 Kuehne SA, Minton NP, et al. Functional intestinal bile acid 7 α -dehydroxylation by *Clostridium*
653 *scindens* associated with protection from *Clostridium difficile* infection in a gnotobiotic mouse
654 model. *Front Cell Infect Microbiol* 2016; 6:191. doi: 10.3389/fcimb.2016.00191
- 655 15. Li J, Dawson PA. Animal models to study bile acid metabolism. *Biochim. Biophys. Acta - Mol.*
656 *Basis Dis.*2019; 1865:895–911. doi: 10.1016/j.bbadis.2018.05.011
- 657 16. Honda A, Miyazaki T, Iwamoto J, Hirayama T, Morishita Y, Monma T, Ueda H, Mizuno S,
658 Sugiyama F, Takahashi S, et al. Regulation of bile acid metabolism in mouse models with
659 hydrophobic bile acid composition. *J Lipid Res* 2020; 61:54–69. doi: 10.1194/jlr.RA119000395
- 660 17. Morris GN, Winter J, Cato EP, Ritchie AE, Bokkenheuser VD. *Clostridium scindens* sp. nov., a
661 Human Intestinal Bacterium with Desmolytic Activity on Corticoids. *Int J Syst Bacteriol* 1985;
662 35:478–81. doi: 10.1099/00207713-35-4-478
- 663 18. Lagkouvardos I, Pukall R, Abt B, Foessel BU, Meier-Kolthoff JP, Kumar N, Bresciani A, Martínez I,
664 Just S, Ziegler C, et al. The Mouse Intestinal Bacterial Collection (miBC) provides host-specific
665 insight into cultured diversity and functional potential of the gut microbiota. *Nat Microbiol*
666 2016; 1:1–15. doi: 10.1038/nmicrobiol.2016.131
- 667 19. Streidl T, Kumar N, Suarez LN, Rohn S, Clavel T. *Extibacter*. In: *Bergey's Manual of Systematics*
668 *of Archaea and Bacteria*. American Cancer Society; 2019. page 1–7. doi:
669 10.1002/9781118960608.gbm01749
- 670 20. Marion S, Studer N, Desharnais L, Menin L, Escrig S, Meibom A, Hapfelmeier S, Bernier-Latmani
671 R. *In vitro* and *in vivo* characterization of *Clostridium scindens* bile acid transformations. *Gut*
672 *Microbes* 2019; 10:481–503. doi: 10.1080/19490976.2018.1549420
- 673 21. Streidl T, Karkossa I, Segura Muñoz RR, Eberl C, Zaufel A, Plagge J, Schmaltz R, Schubert K, Basic
674 M, Schneider KM, et al. The gut bacterium *Extibacter muris* produces secondary bile acids and
675 influences liver physiology in gnotobiotic mice. *Gut Microbes* 2021; 13:1–21. doi:
676 10.1080/19490976.2020.1854008
- 677 22. Mallonee DH, White WB, Hylemon PB. Cloning and sequencing of a bile acid-inducible operon
678 from *Eubacterium* sp. strain VPI 12708. *J Bacteriol* 1990; 172:7011–9.
- 679 23. Ridlon JM, Hylemon PB. Identification and characterization of two bile acid coenzyme A
680 transferases from *Clostridium scindens*, a bile acid 7 α -dehydroxylating intestinal bacterium . *J*
681 *Lipid Res* 2012; 53:66–76. doi: 10.1194/jlr.m020313
- 682 24. Wells JE, Hylemon PB. Identification and Characterization of a Bile Acid 7 α -
683 Dehydroxylation Operon in *Clostridium* sp. Strain TO-931, a Highly Active 7 α -
684 Dehydroxylating Strain Isolated from Human Feces. *Appl Environ Microbiol* 2000; 66:1107–13.
685 doi: 10.1128/AEM.66.3.1107-1113.2000
- 686 25. Funabashi M, Grove TL, Wang M, Varma Y, McFadden ME, Brown LC, Guo C, Higginbottom S,
687 Almo SC, Fischbach MA. A metabolic pathway for bile acid dehydroxylation by the gut
688 microbiome. *Nature* 2020; :1–5. doi: 10.1038/s41586-020-2396-4
- 689 26. Macdonald IA, Hutchison DM. Epimerization versus dehydroxylation of the 7 α -hydroxyl- group
690 of primary bile acids: Competitive studies with *Clostridium absonum* and 7 α -dehydroxylating
691 bacteria (*Eubacterium* SP.). *J Steroid Biochem* 1982; 17:295–303. doi: 10.1016/0022-
692 4731(82)90203-5
- 693 27. Doerner KC, Takamine F, LaVoie CP, Mallonee DH, Hylemon PB. Assessment of fecal bacteria
694 with bile acid 7 α -dehydroxylating activity for the presence of *bai*-like genes. *Appl Environ*
695 *Microbiol* 1997; 63:1185–8.


- 696 28. Vinithakumari AA, Hernandez BG, Ghimire S, Adams S, Stokes C, Jepsen I, Brezina C, Sahin O, Li
697 G, Tangudu C, et al. A model screening pipeline for bile acid converting anti-*Clostridioides*
698 *difficile* bacteria reveals unique biotherapeutic potential of *Peptacetobacter hiranonis*. bioRxiv
699 2021; :2021.09.29.462466. doi: 10.1101/2021.09.29.462466
- 700 29. Ridlon JM. Enzymology and molecular biology of bile acid 7 α - and 7 β - dehydroxylation
701 by the intestinal bacteria *Clostridium scindens* and *Clostridium hylemonae*. PhD Thesis Virginia
702 Commonw Univ 2008; :1–333. doi: <https://doi.org/10.25772/BN62-H676>
- 703 30. Makino I, Nakagawa S. Changes in biliary lipid and biliary bile acid composition in patients after
704 administration of ursodeoxycholic acid. J Lipid Res 1978; 19:723–8. doi: 10.1016/s0022-
705 2275(20)41272-6
- 706 31. Meir K, Kitsberg D, Alkalay I, Szafer F, Rosen H, Shpitzen S, Avi L Ben, Staels B, Fievet C, Meiner
707 V, et al. Human sterol 27-hydroxylase (CYP27) overexpressor transgenic mouse model.
708 Evidence against 27-hydroxycholesterol as a critical regulator of cholesterol homeostasis. J Biol
709 Chem 2002; 277:34036–41. doi: 10.1074/jbc.M201122200
- 710 32. Devendran S, Shrestha R, Alves JMP, Wolf PG, Ly L, Hernandez AG, Méndez-García C, Inboden
711 A, Wiley J, Paul O, et al. *Clostridium scindens* ATCC 35704: Integration of nutritional
712 requirements, the complete genome sequence, and global transcriptional responses to bile
713 acids. Appl Environ Microbiol 2019; 85. doi: 10.1128/AEM.00052-19
- 714 33. Ridlon JM, Devendran S, Alves JM, Doden H, Wolf PG, Pereira G V., Ly L, Volland A, Takei H,
715 Nittono H, et al. The ‘in vivo lifestyle’ of bile acid 7 α -dehydroxylating bacteria: comparative
716 genomics, metatranscriptomic, and bile acid metabolomics analysis of a defined microbial
717 community in gnotobiotic mice. Gut Microbes 2019; :1–24. doi:
718 10.1080/19490976.2019.1618173
- 719 34. Bhowmik S, Jones DH, Chiu HP, Park IH, Chiu HJ, Axelrod HL, Farr CL, Tien HJ, Agarwalla S, Lesley
720 SA. Structural and functional characterization of BaiA, an enzyme involved in secondary bile
721 acid synthesis in human gut microbe. Proteins Struct Funct Bioinforma 2014; 82:216–29. doi:
722 10.1002/prot.24353
- 723 35. Ridlon JM, Harris SC, Bhowmik S, Kang D-JJ, Hylemon PB. Consequences of bile salt
724 biotransformations by intestinal bacteria. Gut Microbes 2016; 7:22–39. doi:
725 10.1080/19490976.2015.1127483
- 726 36. Heinken A, Ravcheev DA, Baldini F, Heirendt L, Fleming RMTT, Thiele I. Systematic assessment
727 of secondary bile acid metabolism in gut microbes reveals distinct metabolic capabilities in
728 inflammatory bowel disease. Microbiome 2019; 7:75. doi: 10.1186/s40168-019-0689-3
- 729 37. Brugiroux S, Beutler M, Pfann C, Garzetti D, Ruscheweyh HJ, Ring D, Diehl M, Herp S, Lötscher
730 Y, Hussain S, et al. Genome-guided design of a defined mouse microbiota that confers
731 colonization resistance against *Salmonella enterica* serovar Typhimurium. Nat Microbiol 2016;
732 2:1–12. doi: 10.1038/nmicrobiol.2016.215
- 733 38. Hofmann AF, Hagey LR. Key discoveries in bile acid chemistry and biology and their clinical
734 applications: History of the last eight decades. J. Lipid Res.2014; 55:1553–95. doi:
735 10.1194/jlr.R049437
- 736 39. Winston JA, Theriot CM. Diversification of host bile acids by members of the gut microbiota.
737 Gut Microbes2020; 11:158–71. doi: 10.1080/19490976.2019.1674124
- 738 40. Ridlon JM, Kang DJ, Hylemon PB. Isolation and characterization of a bile acid inducible 7 α -
739 dehydroxylating operon in *Clostridium hylemonae* TN271. Anaerobe 2010; 16:137–46. doi:

- 740 10.1016/j.anaerobe.2009.05.004
- 741 41. Song I, Gotoh Y, Ogura Y, Hayashi T, Fukiya S, Yokota A. Comparative genomic and physiological
742 analysis against *Clostridium scindens* reveals *Eubacterium* sp. C-25 as an atypical deoxycholic
743 acid producer of the human gut microbiota. *Microorganisms* 2021; 9:2254. doi:
744 10.3390/microorganisms9112254
- 745 42. Bai Y, Zhao T, Gao M, Zou Y, Lei X. A Novel Gene Alignment in *Dorea* sp. AM58-8 Produces 7-
746 Dehydroxy-3 β Bile Acids from Primary Bile Acids. *Biochemistry* 2022; doi:
747 10.1021/acs.biochem.2c00264
- 748 43. Hylemon PB, Melone PD, Franklund C V., Lund E, Bjorkhem I. Mechanism of intestinal 7 α -
749 dehydroxylation of cholic acid: Evidence that allo-deoxycholic acid is an inducible side-product.
750 *J Lipid Res* 1991; 32:89–96.
- 751 44. Masuda N, Oda H, Hirano S, Tanaka H. Enhancement of the 7 α -dehydroxylase activity of a
752 gram-positive intestinal anaerobe by flavins. *Appl Environ Microbiol* 1983; 45:308–9.
- 753 45. Kitahara M, Takamine F, Imamura T, Benno Y. Assignment of *Eubacterium* sp. VPI 12708 and
754 related strains with high bile acid 7 α -dehydroxylating activity to *Clostridium scindens* and
755 proposal of *Clostridium hylemonae* sp. nov., isolated from human faeces. *Int J Syst Evol*
756 *Microbiol* 2000; 50:971–8. doi: 10.1099/00207713-50-3-971
- 757 46. Benno Y, Kitahara M, Takamine F, Imamura T. *Clostridium hiranonis* sp. nov., a human intestinal
758 bacterium with bile acid 7 α -dehydroxylating activity. *Int J Syst Evol Microbiol* 2001; 51:39–
759 44. doi: 10.1099/00207713-51-1-39
- 760 47. Abdallah E, Emile SH, Elfeki H, Fikry M, Abdelshafy M, Elshobaky A, Elgendy H, Thabet W,
761 Youssef M, Elghadban H, et al. Role of ursodeoxycholic acid in the prevention of gallstone
762 formation after laparoscopic sleeve gastrectomy. *Surg Today* 2017; 47:844–50. doi:
763 10.1007/s00595-016-1446-x
- 764 48. Coleman JP, Hudson LL, Adams MJ. Characterization and regulation of the NADP-linked 7 α -
765 hydroxysteroid dehydrogenase gene from *Clostridium sordellii*. *J Bacteriol* 1994; 176:4865–74.
- 766 49. Ferrandi EE, Bertolesi GM, Polentini F, Negri A, Riva S, Monti D. In search of sustainable
767 chemical processes: Cloning, recombinant expression, and functional characterization of the
768 7 α - and 7 β -hydroxysteroid dehydrogenases from *Clostridium absonum*. *Appl Microbiol*
769 *Biotechnol* 2012; 95:1221–33. doi: 10.1007/s00253-011-3798-x
- 770 50. Devlin AS, Fischbach MA. A biosynthetic pathway for a prominent class of microbiota-derived
771 bile acids. *Nat Chem Biol* 2015; 11:685–90. doi: 10.1038/nchembio.1864
- 772 51. Narushima S, Itoh K, Miyamoto Y, Park SH, Nagata K, Kuruma K, Uchida K. Deoxycholic acid
773 formation in gnotobiotic mice associated with human intestinal bacteria. *Lipids* 2006; 41:835–
774 43. doi: 10.1007/s11745-006-5038-1
- 775 52. Eyssen HJ, Parmentier GG, Mertens JA. Sulfated Bile Acids in Germ-Free and Conventional
776 Mice. *Eur J Biochem* 1976; 66:507–14. doi: 10.1111/j.1432-1033.1976.tb10576.x
- 777 53. Han J, Liu Y, Wang R, Yang J, Ling V, Borchers CH. Metabolic profiling of bile acids in human and
778 mouse blood by LC-MS/MS in combination with phospholipid-depletion solid-phase extraction.
779 *Anal Chem* 2015; 87:1127–36. doi: 10.1021/ac503816u
- 780 54. Straniero S, Laskar A, Savva C, Härdfeldt J, Angelin B, Rudling M. Of mice and men: Murine bile
781 acids explain species differences in the regulation of bile acid and cholesterol metabolism. *J*
782 *Lipid Res* 2020; 61:480–91. doi: 10.1194/jlr.RA119000307

- 783 55. Sayin SI, Wahlström A, Felin J, Jäntti S, Marschall HU, Bamberg K, Angelin B, Hyötyläinen T,
784 Orešič M, Bäckhed F. Gut microbiota regulates bile acid metabolism by reducing the levels of
785 tauro-beta-muricholic acid, a naturally occurring FXR antagonist. *Cell Metab* 2013; 17:225–35.
786 doi: 10.1016/j.cmet.2013.01.003
- 787 56. Dawson JA, Mallonee DH, Bjorkhem I, B P. Expression and characterization of a C24 bile acid
788 7 α -dehydratase from *Eubacterium* sp. strain VPI 12708 in *Escherichia coli*. *J Lipid Res* 1996;
789 37:1258–67.
- 790 57. Laing E, Mersinias V, Smith CP, Hubbard SJ. Analysis of gene expression in operons of
791 *Streptomyces coelicolor*. *Genome Biol* 2006; 7:R46. doi: 10.1186/gb-2006-7-6-r46
- 792 58. Marion S, Desharnais L, Studer N, Dong Y, Notter MD, Poudel S, Menin L, Janowczyk A, Hettich
793 RL, Hapfelmeier S, et al. Biogeography of microbial bile acid transformations along the murine
794 gut. *J Lipid Res* 2020; 61:1450–63. doi: 10.1194/jlr.RA120001021
- 795 59. Wolf PG, Byrd DA, Cares K, Dai H, Odoms-Young A, Gaskins HR, Ridlon JM, Tussing-Humphreys
796 L. Bile Acids, Gut Microbes, and the Neighborhood Food Environment—a Potential Driver of
797 Colorectal Cancer Health Disparities. *mSystems* 2022; 7. doi: 10.1128/msystems.01174-21
- 798 60. National Research Council. Nutrient Requirements of the Mouse. *Nutr Requir Lab Anim* 1995;
799 :80–102.
- 800 61. Uchimura Y, Wyss M, Brugiroux S, Limenitakis JP, Stecher B, McCoy KD, Macpherson AJ.
801 Complete Genome Sequences of 12 Species of Stable Defined Moderately Diverse Mouse
802 Microbiota 2: TABLE 1 . *Genome Announc* 2016; 4:4–5. doi: 10.1128/genomea.00951-16
- 803 62. Team RC. R: A language and environment for statistical computing. 2023;
- 804 63. RStudio Team (2020). RStudio: Integrated Development for R. 2020;


805

806 **Figures**




		3-oxochenodeoxycholic acid	3-oxoCDCA	=O		α -OH	
		3-oxolithocholic acid	3-oxoLCA	=O			
		3-oxoursodeoxycholic acid [†]	3-oxoUDCA	=O		β -OH	
		7-oxodeoxycholic acid	7-oxoDCA	α -OH		=O	α -OH
		7-oxolithocholic acid	7-oxoLCA	α -OH		=O	
		12-oxochenodeoxycholic acid	12-oxoCDCA	α -OH			=O
		12-oxolithocholic acid	12-oxoLCA	α -OH			=O
		Isoursodeoxycholic acid [†]	isoUDCA	β -OH		β -OH	
Rodent	primary	α -Muricholic acid	α MCA	α -OH	β -OH	α -OH	
		B-Muricholic acid	β MCA	α -OH	β -OH	β -OH	
	secondary	Murideoxycholic acid	MDCA	α -OH	β -OH		
		3-oxo- α -muricholic acid [†]	3-oxo α MCA	=O	β -OH	α -OH	
		3-oxo- β -muricholic acid [†]	3-oxo β MCA	=O	β -OH	β -OH	
		3-oxomurideoxycholic acid [†]	3-oxoMDCA	=O	β -OH		
		6-oxo- α -muricholic acid [†]	6-oxo α MCA	α -OH	=O	α -OH	
		6-oxo- β -muricholic acid [†]	6-oxo β MCA	α -OH	=O	β -OH	
		6-oxomurideoxycholic acid [‡]	6-oxoMDCA	α -OH	=O		
		7-oxomurideoxycholic acid [†]	7-oxoMDCA	α -OH	β -OH	=O	
ω -Muricholic acid [†]	ω MCA	α -OH	α -OH	β -OH			

807 Figure 1. List of deconjugated human and rodent bile acids (BAs) discussed here. The characteristic that distinguishes BAs
808 is the presence of a hydroxyl group at the C-3, C-6, C-7 and/or C-12 position. The hydroxyl groups can be in α - or β -
809 conformation, oxidised into a ketone group, or fully removed (dehydroxylated BA). CA and CDCA are primary BAs of both
810 humans and rodents whereas MCAs are exclusively produced by rodents. (*) UDCA is a primary BA in rodents while it is a
811 secondary BA in humans where the gut microbes epimerise it from CDCA. (†) Bile acids that might have been detected in
812 this study but for which no standards were available. (‡) Also known as 6-oxolithocholic acid (6-oxoLCA). See
813 Supplementary Table 3 for full chemical names of the BAs.
814




815
816
817
818
819
820




821
822 **Figure 3. *In vitro* 7 α -dehydroxylation of CDCA.** The transformation of CDCA into secondary bile acids was tested with and
823 without co-induction with 100 μ M of ¹³C-CA. 200 μ M of CDCA were used based on previous experiments by Marion *et al.*
824 (A) *Clostridium scindens* ATCC 35704, (B) *C. scindens* VPI 12708 and (C) *E. muris* DSM 28561 (SJ24). Bile acids were extracted
825 from the suspended biomass. Error bars represent the standard deviation of the mean of biological triplicates.

826


827



828
 829 **Figure 4. *In vitro* 7-dehydroxylation of UDCA.** The transformation of 100 µM of UDCA into secondary bile acids was tested
 830 with and without co-induction with 100 µM of ¹³C-CA. (A) *Clostridium scindens* ATCC 35704, (B) *C. scindens* VPI 12708 and
 831 (C) *Extibacter muris* DSM 28561 (SJ24) were grown anaerobically in BHIS-S. Bile acids were extracted from suspended
 832 biomass. Two compounds were detected that could not be identified due to missing standards but their oxidative state
 833 can be estimated based on their ionised mass. X-oxoUDCA had the same mass as other bile acids with one ketone group
 834 and one hydroxyl group. The other unidentified compound had the same mass as UDCA and therefore it is likely to be an
 835 isoform with a 3β conformation. The retention times for these compounds was unique and therefore could not be
 836 identified further. Concentration values of the unknown BAs could only be estimated for the same reason. Error bars
 837 represent the standard deviation of the mean of biological triplicates.
 838




839
 840 **Figure 5. *In vitro* 7-dehydroxylation of αMCA.** The transformation of 100 µM of αMCA into secondary bile acids was tested
 841 with and without co-induction with 100 µM of ¹³C-CA. (A) *Clostridium scindens* ATCC 35704, (B) *C. scindens* VPI 12708 and
 842 (C) *Extibacter muris* DSM 28561 (SJ24) were grown anaerobically in BHIS-S. Bile acids were extracted from suspended
 843 biomass. Several compounds were detected that could not be identified due to missing standards but their oxidative state
 844 can be estimated based on their ionised mass. X- or Y- oxoαMCA had the same mass as other bile acids with one ketone
 845 group and two hydroxyl groups. The other unidentified compound had the same mass as secondary bile acids that have
 846 been dehydroxylated (-1 -OH), have one ketone group and one hydroxyl group. The retention times for these compounds
 847 did not correspond to that of any known standard. Concentration values of the unknown BAs could only be semi-
 848 quantitative for the same reason. Error bars represent the standard deviation of the mean of biological triplicates.
 849




850
851
852
853
854
855
856
857
858

Figure 6. *bai* gene expression in the presence of CA (first panel) or in that of various primary BAs either uninduced or and co-induced with ¹³C-CA. Data for the CA-only condition correspond to the pooled expression results from the two sets of experiments (referred to as uninduced and co-induced) that both include this condition, as described in the text. The expression (normalised to at least three reference genes) is relative to the no BA condition including an equivalent volume of solvent (ethanol). (A) *Clostridium scindens* ATCC 35704, (B) *C. scindens* VPI 12708 and (C) *Extibacter muris* DSM 28561 (SJ24) gene expression of *baiCD*, *baiE* (part of the *bai* operon), and accessory genes *baiJ* and *baiO* (only in *E. muris* DSM SJ24) was measured. CA, UDCA, αMCA, βMCA and the co-inducing ¹³C-CA were used at 100 μM, CDCA was used at 200 μM. A detailed view of the *C. scindens* VPI 12708 uninduced vs 13C-CA co-induced in the CDCA group is found in

859 **Supplementary Figure 4. Coloured dots represent the average and error bars represent the standard deviation of 12**
 860 **replicates. Some error bars may look elongated due to the logarithmic scale of the Y axis. (***) indicates a *p*-value < 0.001**
 861 **in a linear model analysis comparing the uninduced vs ¹³C-CA co-induced factor for each *bai* gene.**
 862
 863




864
 865 **Figure 7. *In vitro* transformation of BA cocktails by *E. muris* DSM SJ24. The transformation of several BAs at 50 µM by *E.***
 866 ***muris* DSM 28561 (SJ24) was tested anaerobically in 25 mL of BHIS-S. Different cocktails were prepared based on their**
 867 **similarity. Tauro-conjugated BAs (A). Oxidised BAs (B), Sulfonated BAs (C) or the secondary BA ωMCA (D) which is present**
 868 **in the murine BA pool. Three time points were taken for BA extraction from suspended biomass. An additional sample of**
 869 **1 mL was taken at 16 hours for RNA extraction and RT-qPCR analysis. Minute concentrations (<2 µM) of CA (A) and βMCA**
 870 **(B) were detected, most likely as impurities from the standards used as they were detected from time 0 and**
 871 **concentrations remained stable. Error bars represent the standard deviation of the mean of biological replicates.**
 872



873
 874 **Figure 8. *In vitro* 7-DH-ion of CA by *E. muris* SJ24 amended with cecal content. The transformation of 100 µM of CA into**
 875 **secondary BAs was tested with and without the amendment of cecal content. A control group with only CA (A) was used**
 876 **as intra-assay reference vs (B) cecal content from germ-free mice and (C) cecal content from sDMDMm2 mice. 25 mg of**
 877 **cecal content were added to 25 mL of BHIS-S. The mass imbalance between the added CA (100 µM) and the measured**

878 (aprox. 80 μ M) can be attributed to the presence of CoA- forms that cannot currently be quantified due to lack of
879 standards. Error bars represent the standard deviation of biological triplicates. Data from the control groups of this
880 experiment can be found in Supplementary Figure 7.
881



882
883 Figure 9. *In vivo* *E. muris* SJ24 *bai* expression. The expression (normalised to at least three reference genes) is relative to
884 a non-colonised sDMDM2 control group. Each bar represents the average value from five biological replicates with four
885 technical replicates each. Error bars represent the standard deviation of the mean.